(Finance) – Svas Biosanaa company listed on Euronext Growth Milan and active in the production of medical devices for healthcare facilities, has closed i first nine months of 2024 with revenues consolidated amounts of 85.9 million euros, up 5.3% compared to the same period of the previous year (81.6 million). Significant increases were recorded in the Mark Medical Business Units – marketing of specialist medical devices in Eastern Europe (+9.8%) and Bormia (+19.6%).
“We are very satisfied with the constant growth that Svas Biosana continues to record – commented theCEO Umberto Perillo – Quarter after quarter the company has been able to maintain a positive trend, confirming itself among the main players in the healthcare sector. The progress recorded reflects the Group’s ability to adapt to evolving market needs and the effectiveness of our international expansion strategy. These results lead us to continue with determination in the direction undertaken, confident that the path of consolidation and growth will continue into the future.”